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Abstract
Background
Extraintestinal manifestations (EIM) contribute significantly to the burden of disease in
inflammatory bowel disease (IBD). Pain is a leading symptom in IBD and could be seen as
an EIM itself. Treatment of IBD associated pain is challenging and insufficiently studied. A
better knowledge on the association of pain and IBD specific treatment is warranted to
improve the management of IBD patients.
Methods
All patients of the Swiss IBD Cohort Study (SIBDCS) (n = 2152) received a questionnaire
regarding pain localization, pain character, and the use of IBD specific medication.
Results
1263 completed questionnaires were received. Twenty-one out of 184 patients (10%)
receiving anti-TNF treatment compared to 142 out of 678 patients (21%) not receiving anti-
TNF medication reported elbow pain (p = 0.002) while 28 out of 198 patients (14%) receiving
steroid treatment significantly more often reported elbow pain compared to 59 from 696
patients (8%) not receiving steroids (p = 0.021). Furthermore, we found significantly more
female patients under anti-TNF treatment to report knee/ lower leg pain and ankle/ foot pain
compared to their male counterparts (36% vs. 20% and 22% vs. 10%, respectively, p =
0.015 for both comparisons). The frequency of knee, lower leg, ankle and foot pain was
especially low in male patients under anti-TNF treatment, indicating a high benefit of male
patients from anti-TNF therapy regarding EIM.
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Conclusions
The frequency of elbow pain was lower in IBD patients treated with anti-TNF but higher in
patients treated with steroids.
Introduction
Pain is a common symptom in patients with inflammatory bowel disease (IBD) [1, 2]. In a
recent study we showed that the vast majority of patients (71%) within the Swiss IBD Cohort
Study experienced pain during their disease course and that for 52% of the patients pain was a
longstanding problem [3]. Abdominal pain can be a direct or indirect consequence of intesti-
nal inflammation; however, extraintestinal manifestations (EIM) of IBD can also cause pain
and pain in itself can be seen as an EIM [4–6]. The most common EIM of IBD are arthropa-
thies [5, 7–17]. Also, in our former study we could show that pain has a substantial impact on
health-related quality of life (HRQOL) of IBD patients, as the general quality of life was signifi-
cantly lower in patients suffering from pain compared to those without pain [3]. Such a rela-
tionship has also been described in other chronic diseases [18–21].
Treatment of both, IBD and IBD associated pain is challenging. The mainstay of IBD treat-
ment includes systemic immunosuppressive medications, such as corticosteroids, anti-tumor
necrosis factor (TNF) antibodies or immunomodulators. Furthermore, the management of an
acute flare differs from the strategies for maintenance of remission [22, 23]. Moreover, pres-
ence of EIM will also influence the choice of a treatment regime. For instance, anti-TNF ther-
apy is known to be very effective regarding gut inflammation as well as arthropathies/ arthritis.
Furthermore, non-steroidal anti-inflammatory drugs (NSAIDs) can very effectively medi-
ate pain relieve due to their analgetic and also anti-inflammatory effects. However, due to the
risk of disease exacerbation and induction of flares their use in IBD is limited [24–30].
Here, we used the well-characterized patient collective of the Swiss IBD Cohort Study
(SIBDCS) to study the association of pain and IBD treatment with a focus on anti-TNF
treatment.
Methods
Ethics consideration
Ethics approval was obtained from the regional Swiss Ethics Committees in which cohort par-
ticipants were enrolled (Commission d’e´thique du Canton de Vaud, Lausanne, Switzerland/
Protocol no. 33/06). Written, informed consent was obtained from each patient included in
the study. The study protocol conforms to the ethical guidelines of the 1975 Declaration of
Helsinki as reflected in a priori approval by the institution’s human research committee.
Study design
Patients of the nationwide SIBDCS have been prospectively included since 2006 with a yearly
follow-up. The cohort goals und methodology of SIBDC have been described elsewhere[31].
A questionnaire addressing various aspects of pain including pain duration localization and
frequency was mailed to 2152 SIBDC patients, representing the entire cohort. The question-
naire also inquired about the use of pain specific medication in detail. Our questionnaire con-
tained several questions from a validated German pain questionnaire [32]. The questionnaire
was used in a German and in a French version. Further details of the questionnaires including
IBD specific treatment and pain
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the fully originally used French and German versions are described elsewhere [3]. Basic epide-
miological and clinical data including the use of IBD specific therapy was retrieved from the
SIBDCS databases. All data are stored in Microsoft Access (Microsoft Corporation) databases.
Statistical analysis
Descriptive statistical analyses were performed: Categorical variables were summarized as fre-
quencies and percentages, whereas quantitative variables as median and range. To assess dif-
ferences in categorical data distribution between groups of different sizes, Fisher’s exact test
was used.
The statistical analysis was performed using GraphPad Prism 7 for MacOS. A p-value
of<0.05 was considered statistically significant.
Results
Patient’s characteristics
The patients’ characteristics shown in Table 1 have been described previously [3]. In brief:
1263 out of 2152 patients completed the questionnaires (response rate 59%). 599 out of 1263
patients were male (47%) and 664 female (53%). The median age was 47 years. Extraintestinal
manifestations (EIM) of IBD were present in 699 patients (55%). The median IBD disease
duration was 15 years (mean: 15 years, range: 0–57 years). The vast majority of patients (894/
1263, 71%) reported the experience of pain in general during the course of the disease. Table 2
shows the frequency of IBD specific treatment.
Association between IBD specific treatment and pain localization
When comparing the use of IBD specific medication and ten different pain localizations, we
found several significant differences. Regarding elbow pain, only 21 patients (10%) receiving
anti-TNF treatment compared to 142 patients (21%) not receiving anti-TNF were affected
(p = 0.002). Other pain localizations did not reveal significant differences regarding anti-TNF
treatment (Table 3).
Comparing other IBD specific therapy and the different pain localization, we found patients
not receiving steroid treatment significantly less often to be suffering from elbow pain com-
pared to patients receiving steroids (8% vs. 14%; p = 0.021). For the evaluation of other pain
Table 1. Patient characteristics.
Patient characteristics Number of patients (%)
Gender Female 664 (53)
Male 599 (47)
Diagnosis CD 679 (54)
UC 556 (44)
IC 28 (2)
Sum 1263 (100)
Pain Yes 894 (71)
No 369 (29)
EIM Yes 699 (55)
No 564 (45)
Disease duration (Years) Average 15
Min-Max 0–57
https://doi.org/10.1371/journal.pone.0215738.t001
IBD specific treatment and pain
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localizations and other IBD specific therapy (5-ASA, calcineurin-inhibitors, immunomodula-
tors) no significant differences were observed (S1–S5 Tables).
Association between IBD specific treatment and duration of pain
Duration of pain did not differ between patients on anti-TNF treatment versus those not on
anti-TNF treatment (Table 4). The duration of pain was also not influenced by other IBD spe-
cific medications (Steroids, 5-ASA, Antibiotics, Calcineurin-inhibitors, Immunomudulators)
also, no significant differences were observed (S6–S10 Tables).
Association between IBD specific treatment and frequency of pain
The frequency of pain in patients with and without anti-TNF treatment did not significantly
differ (Table 5). When comparing the pain frequencies of patients taking other IBD specific
medications (steroids, 5-ASA, antibiotics, calcineurin-inhibitors, immunomodulators), also
no significant differences were observed (S11–S15 Tables).
Association between IBD specific treatment and pain character
Further, there was no association between the pain character and the use of IBD specific medi-
cation. 36 patients (20%) on anti-TNF treatment described their pain to be constant with slight
fluctuations compared to 115 patients (19%) without anti-TNF treatment (p>0.999). Constant
pain with strong fluctuations was reported by 15 patients (8%) using anti-TNF treatment and
by 64 patients (11%) not receiving anti-TNF treatment (p = 0.331). 115 patients (61%) with
TNF treatment and 349 (58%) without anti-TNF treatment experienced pain attacks with pain
Table 2. IBD specific treatment.
IBD treatment Number of patients (%)
with pain without pain
Anti-TNF 216 (24.2) 100 (27.1)
Steroids 198 (22.1) 73 (19.8)
5-aminosalicylic acid (5-ASA) 334 (37.4) 136 (36.9)
Antibiotics 11 (1.2) 6 (1.6)
Calcineurin-Inhibitors 12 (1.3) 5 (1.4)
Immunomodulators 316 (35.3) 125(33.9)
https://doi.org/10.1371/journal.pone.0215738.t002
Table 3. Pain localization.
Anti-TNF No anti-TNF
Pain localization N (%) N (%) p-value
Head 56 (26) 147 (21.7) 0.193
Neck 28 (13) 95 (14) 0.735
Finger/hand 53 (24.5) 142 (20.9) 0.297
Elbow 21 (9.7) 142 (20.9) 0.002
Shoulder 44 (20.4) 138 (20.4) >0.999
Back 77 (35.6) 236 (34.8) 0.869
Hip/thigh 52 (24) 162 (23.9) >0.999
Knee/lower leg 61 (28.2) 181 (26.7) 0.660
Ankle/foot 35 (16.2) 109 (16.1) >0.999
Abdomen 105 (48.6) 375 (55.3) 0.099
https://doi.org/10.1371/journal.pone.0215738.t003
IBD specific treatment and pain
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free intervals (p = 0.554). Pain attacks with constant pain were reported by 30 patients (16%)
receiving anti-TNF treatment compared to 75 (12%) not receiving anti-TNF (p = 0.268).
When comparing the pain character of patients receiving other IBD specific medication (ste-
roids, 5-ASA, antibiotics, calcineurin-inhibitors, immunomodulators), no significant differ-
ences across treatment groups were seen (S16–S21 Tables).
Association between IBD specific treatment and duration of pain attacks
Moreover, the duration of pain attacks was not influenced by IBD specific medication
(Table 6), neither with regards to anti-TNF nor other agents to treat IBD, including steroids,
5-ASA, Antibiotics, Calcineurin-Inhibitors, Immunmodulators (S22–S26 Tables).
Comparison of pain localization of male and female patients with and
without anti-TNF therapy
From a total of 894 patients, a similar fraction of male and female patients (24% for both)
received anti-TNF therapy (Fig 1).
When comparing the pain localizations of male and female patients receiving anti-TNF
treatment significantly fewer male patients with anti-TNF treatment suffered from knee/
lower leg pain compared to female patients receiving anti-TNF therapy (20% vs. 36%;
p = 0.015). Also, significantly fewer male patients receiving anti-TNF treatment reported
ankle/ foot pain compared to female patients with anti-TNF treatment (10% vs. 22%;
p = 0.015). For the other pain localizations, no differences regarding gender were seen
(Table 7).
We did not observe any differences in pain localizations in patients with versus without
anti-TNF-therapy, neither in male nor female patients (Tables 8 and 9).
Table 4. Duration of pain.
Anti-TNF No anti-TNF
Pain peroid N (%) N (%) p-value
<1 month 6 (2.7) 9 (1.3) 0.218
1 month-½ year 20 (9.3) 37 (5.5) 0.054
½ year-1 year 13 (6) 46 (6.8) 0.608
1–2 years 18 (8.3) 61 (9) 0.890
2–5 years 51 (23.6) 164 (24.2) 0.927
>5 years 108 (50) 361 (53.2) 0.434
https://doi.org/10.1371/journal.pone.0215738.t004
Table 5. Frequency of pain.
Anti-TNF No anti-TNF
Pain Frequency N (%) N (%) p-value
Several times daily 49 (28.2) 115 (22) 0.099
1x/day 11 (6.3) 34 (6.5) >0.999
Several times per week 34 (19.5) 100 (19.1) 0.911
1x/week 11 (6.3) 26 (5) 0.557
Several times per month 28 (16.1) 102 (19.5) 0.369
1x/month 12 (6.9) 55 (10.5) 0.182
<1x/month 29 (16.7) 91 (17.4) 0.907
https://doi.org/10.1371/journal.pone.0215738.t005
IBD specific treatment and pain
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Discussion
In our study population 5-aminosalycylicacid (5-ASA) (37%) was the most frequently used
IBD specific medication, followed by immunomodulators (35%) and anti-TNF antibodies
(24%). As for anti-TNF, Vavricka et al. showed that in more than 40% of the cases, this therapy
regime is initiated to treat EIM rather than bowel inflammation and over 70% showed a clini-
cal response of EIM to anti-TNF therapy [6]. Our study supports these findings: we could
show that significantly less patients on anti-TNF reported elbow pain compared to patients
not on anti-TNF. Of note, significantly more patients on steroid treatment reported elbow
pain. Refrences to support these findings are lacking.
Regarding gender specific differences in treatment of EIM/ pain in IBD patients, data is not
consistent. Concerning IBD treatment, Lopetusa et al. found no general influence of the gen-
der on the therapy of ulcerative colitis (UC) with anti-TNF (infliximab) [33]. However, female
patients with steroid-refractory UC and successive anti-TNF treatment showed an increased
1-year remission rate and a cumulative non-colectomy rate. In contradiction, Lopetusa et al.
found a lower rate of response to treatment and of disease remission in female patients under
TNF inhibitors with axial spondyloarthritis[34]. As for possible explanations, Nguyen et al.
showed that the three biomarkers praealbumin, platelet factor 4 and S100A12 accurately pre-
dict the response of patients with rheumatoid arthritis to TNF inhibitors[35]. Further studies
about a gender-specific correlation of these marker could reveal useful findings. In our study,
we found that statistically significant less male patients with anti-TNF treatment reported
knee/ lower leg and foot/ ankle pain compared to female patients with anti-TNF. This data
may indicate that there is a gender difference regarding the effect of anti-TNF therapy for
EIM.
One strength of our study is the size of the cohort with 1263 completed questionnaires.
Together with our former study evaluating pain in the SIBDCS [3] it is, to the best of our
knowledge, the largest evaluation of pain and the use of IBD specific therapy in IBD up to date.
However, our study also has limitations. Due to the study design and the lack of control
regarding unreturned questionnaires, a reporting bias cannot be excluded. Patients who actu-
ally suffer from pain due to IBD therefore might be overrepresented compared to patients
without pain, since the former might be more motivated to return the questionnaire. The
patients not responding to the survey might have represented a different phenotype regarding
our topic of interest. The existing data of the SIBDCS doesn’t include any information about
pain, preventing us from compairing pain specific parameters between responders and non-
responders. Furthermore, regarding the use of IBD specific therapy and pain localizations, we
do not have information on the reason to initiate medical therapy (i.e. EIM vs. intestinal activ-
ity of IBD or both) and how high the prevalence of pain has been before treatment initiation.
Our statistical evaluation of the data represents another limitation. We have performed a
mostly derscriptive analysis of the dataset. To remain a high response rate and not no
Table 6. Duration of pain attacks.
Anti-TNF No anti-TNF
Duration of pain attacks N (%) N (%) p-value
Seconds 26 (14.9) 61 (11.9) 0.295
Minutes 56 (32) 158 (30.8) 0.777
Hours 55 (31.4) 175 (34) 0.577
<3 days 21 (12) 67 (13) 0.793
>5 days 17 (9.7) 53 (10.3) 0.885
https://doi.org/10.1371/journal.pone.0215738.t006
IBD specific treatment and pain
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overstrain the goodwill of the patients, we intended to keep our questionnaire on a simplistic
level. We further see the sizes of our subgroups as a potential limitation. We are aware that
small subgroups may be linked to random positive findings. In comparison to other studies
about pain in IBD, the subgroups examined here are not considerably small. Furthermore, we
aimed to include as many pain localizations as possible to thoroughly analyse the distribution
of pain. Additionally, our findings, particularly regarding Anti-TNF, match the clinical obser-
vations, depicting a genuine outcome.
In summary, we could show that the frequency of elbow pain was lower in patients treated
with anti-TNF but higher under steroid treatment. There were no significant differences
regarding the use IBD specific therapy and the character, duration and frequency of pain. Fur-
thermore, our data point towards a higher treatment benefit of anti-TNF with regards to EIM
in male patients which should be followed up in future studies.
Fig 1. Male and female patients with and without Anti-TNF.
https://doi.org/10.1371/journal.pone.0215738.g001
Table 7. Pain localization of male vs. female patients with anti-TNF.
Anti-TNF/ male Anti-TNF/ female
Pain localization N (%) N (%) p-value
Back 32 (30.8) 45 (40.2) 0.158
Knee/lower leg 21 (20.2) 40 (35.7) 0.015
Elbow 11 (10.6) 10 (8.9) 0.819
Hip/thigh 22 (21.2) 30 (26.8) 0.344
Finger/hand 21 (20.2) 32 (28.6) 0.158
Ankle/foot 10 (9.6) 25 (22.3) 0.015
https://doi.org/10.1371/journal.pone.0215738.t007
IBD specific treatment and pain
PLOS ONE | https://doi.org/10.1371/journal.pone.0215738 April 25, 2019 7 / 12
Supporting information
S1 Table. Pain localization (Steroids).
(PDF)
S2 Table. Pain localization (5-aminosalicylic acid).
(PDF)
S3 Table. Pain localization (Immunomodulators).
(PDF)
S4 Table. Pain localization (Antibiotics).
(PDF)
S5 Table. Pain localization (Calcineurin-Inhibitors).
(PDF)
S6 Table. Duration of pain (Steroids).
(PDF)
S7 Table. Duration of pain (5-aminosalicylic acid).
(PDF)
S8 Table. Duration of pain (Antibiotics).
(PDF)
S9 Table. Duration of pain (Calcineurin-Inhibitors).
(PDF)
S10 Table. Duration of pain (Immunomodulators).
(PDF)
Table 8. Pain localization of male patients with vs. without anti-TNF.
Anti-TNF/ male No anti-TNF/ male
Pain localization N (%) N (%) p-value
Back 32 (30.8) 122 (38) 0.198
Knee/lower leg 21 (20.2) 89 (27.7) 0.156
Elbow 11 (10.6) 28 (8.7) 0.561
Hip/thigh 22 (21.2) 73 (22.7) 0.787
Finger/hand 21 (20.2) 69 (21.5) 0.890
Ankle/foot 10 (9.6) 51 (15.9) 0.146
https://doi.org/10.1371/journal.pone.0215738.t008
Table 9. Pain localization of female patients with vs. without anti-TNF.
anti-TNF/female No anti-TNF/female
Pain Localisation N (%) N (%) p-value
Back 45 (40.2) 114 (31.9) 0.110
Knee/lower leg 40 (35.7) 92 (25.8) 0.053
Elbow 10 (8.9) 38 (10.6) 0.721
Hip/thigh 30 (26.8) 89 (24.9) 0.709
Finger/hand 32 (28.6) 73 (20.4) 0.090
Ankle/foot 25 (22.3) 58 (16.2) 0.156
https://doi.org/10.1371/journal.pone.0215738.t009
IBD specific treatment and pain
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S13 Table. Frequency of pain (Antibiotics).
(PDF)
S14 Table. Frequency of pain (Calcineurin-Inhibitors).
(PDF)
S15 Table. Frequency of pain (Immunomodulators).
(PDF)
S16 Table. Pain character (Anti-TNF).
(PDF)
S17 Table. Pain character (Steroids).
(PDF)
S18 Table. Pain character (5-aminosalicylic acid).
(PDF)
S19 Table. Pain character (Antibiotics).
(PDF)
S20 Table. Pain character (Calcineurin-Inhibitors).
(PDF)
S21 Table. Pain character (Immunomodulators).
(PDF)
S22 Table. Duration of pain attacks (Steroids).
(PDF)
S23 Table. Duration of pain attacks (5-aminosalicylic acid).
(PDF)
S24 Table. Duration of pain attacks (Antibiotics).
(PDF)
S25 Table. Duration of pain attacks (Calcineurin-Inhibitors).
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S26 Table. Duration of pain attacks (Immunomodulators).
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